What insurance policy changes affect code M08.3?

There are 3 tracked policy changes affecting code M08.3, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code M08.3?

Payers that have issued tracked updates for code M08.3 include: Aetna.

How do I get notified when code M08.3 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code M08.3. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code M08.3?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

M08.3 Insurance Policy Changes

ICD-10 M08.3 is officially defined as "Juvenile rheumatoid polyarthritis (seronegative)." code M08.3 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M08.3 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Effective Jan 7, 2026Medium impact
Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Blocking Agents (CPB 1091, reviewed 2026-10-16)
Aetna considers measurement of antidrug antibodies and or serum drug levels for adalimumab, certolizumab, golimumab, or infliximab medically necessary for members with Crohn's disease or ulcerative colitis when there is documentation of a loss of response to one of these medications, or for proactive monitoring in members 21 years of age or younger with a confirmed diagnosis of IBD. Aetna considers serum antibody measurements for anti-TNF therapies experimental, investigational, or unproven for all other indications, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, spondyloarthritis, and uveitis. Anti-histone antibody measurement for monitoring infliximab and DNA or mRNA biomarker measurement for predicting therapeutic response in IBD are also considered experimental, investigational, or unproven.
Aetna · Identified Aug 19, 2026Medium impact
Mechanical Stretching Devices for Contracture and Joint Stiffness (CPB 0405, reviewed 2026-06-30)
Aetna covers dynamic splinting devices for the knee, elbow, wrist, finger or toe when there are documented signs and symptoms of significant motion stiffness or loss and the splint is used as an adjunct to occupational or physical therapy at least 3 weeks after injury or surgery, or when the member has a documented history of motion loss in a joint and is in the acute post-operative period after a second or subsequent surgery. The policy also covers the dynamic adjustable ankle extension/flexion device (e.g., JAS Ankle) for contractures, the EZ Turnbuckle orthosis after open reduction internal fixation for radial head fracture, and continued mechanical stretching when documented improvement in range of motion is shown. Dynamic splinting for carpal tunnel syndrome, cerebral palsy, foot drop associated with neuromuscular diseases, multiple sclerosis, stroke and plantar fasciitis, JAS splints, PASS devices such as the ERMI flexionators and extensionators, SaeboMas, Medi-Dyne Prostretch, and mechanical stretching for skin graft contracture are considered experimental, investigational or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Rheumatic Diseases: Selected Tests (CPB 0866, reviewed 2025-12-22)
Aetna considers HLA-B27 testing medically necessary for diagnosing ankylosing spondylitis and Reiter's syndrome (reactive arthritis), anti-CCP antibodies medically necessary for diagnosing rheumatoid arthritis, a myositis antibody panel medically necessary for diagnosing inflammatory myopathy, and anti-dsDNA antibodies medically necessary for evaluating and managing systemic lupus erythematosus. The UBA1 mutation test (QClamp Plex VEXAS) is medically necessary for detecting VEXAS syndrome in individuals aged 18 years or older who present with clinical features of the syndrome. Aetna considers the listed biomarker tests experimental, investigational or unproven because their effectiveness has not been established, including the aiSLE DX indices, PrismRA, Vectra DA, the Avise tests, anti-MCV antibodies, the Early Sjogren's Syndrome Profile, and anti-CCP antibodies for indications other than rheumatoid arthritis.

Watch M08.3

Get one email when a payer policy names M08.3, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Blocking Agents (CPB 1091, reviewed 2026-10-16)

Mechanical Stretching Devices for Contracture and Joint Stiffness (CPB 0405, reviewed 2026-06-30)

Rheumatic Diseases: Selected Tests (CPB 0866, reviewed 2025-12-22)

What insurance policy changes affect code M08.3?

Which payers have updated policy for code M08.3?

How do I get notified when code M08.3 policy changes?

Why do payers change policies for code M08.3?